RESEARCH TRIANGLE PARK – Drug giant GlaxoSmithKline has struck a deal worth as much as $26.5 million for development and commercialization rights to wearable pain relief technology made by NeuroMetrix, a Massachusetts-based firm.

The deal involves Quell Wearable Pain Relief Technology, which NeuroMetrix describes as “an advanced, wearable technology for treating chronic pain.  It can be worn during the day while active and at night while sleeping. Quell is drug-free and has been cleared by the FDA for treatment of chronic pain without a prescription.”

Under the deal, GSK gains ownership of Quell outside of the U.S. and the three firms will co-found further development over three years.

GSK Consumer Healthcare pays $5 million upfront for Quell assets outside the U.S. and as much as $21.5 million if certain milestones are met

Shai Gozani, Chief Executive Officer of NeuroMetrix, added: “We will continue to focus on building Quell into a leading U.S. consumer healthcare brand while collaborating with GSK on Quell product development and supporting their international commercialization efforts.  We believe that GSK is our ideal Quell partner as we share a deep commitment to science-based therapies and to the health and quality of life of our customers.”

GSK employs several thousand people in the Triangle area.